Formulation and statistical optimization of novel double-incorporated PLA-PLGA microparticles within an alginate-pectinate platform for the delivery of nicotine

Journal of Microencapsulation

Volumn 23, Issue 2, 2006, Pages 153-167

  Singh, Neha ^a   Seedat, Fehmeeda ^a   Pillay, Viness ^a   Sweet, Joe L ^b   Danckwerts, Michael P ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Double incorporation of PLA PLGA microparticles; Nicotine; Zinc alginate pectinate polyspheres

Indexed keywords

ALGINIC ACID; GLUCONATE ZINC; NICOTINE; PECTIN; POLYGLACTIN; POLYLACTIC ACID;

ALZHEIMER DISEASE; ARTICLE; ARTIFICIAL NEURAL NETWORK; BRAIN; COMPUTER MODEL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG IMPLANT; DRUG RELEASE; GELATION; INOTROPISM; MULTIPLE REGRESSION; PARTICLE SIZE; POSITIVE FEEDBACK; STATISTICAL ANALYSIS;

ALGINATES; ALGORITHMS; CROSS-LINKING REAGENTS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; GLUCURONIC ACID; HEXURONIC ACIDS; LACTIC ACID; MICROSPHERES; NICOTINE; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS; REGRESSION ANALYSIS;

EID: 33744904223     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.1080/02652040500435139     Document Type: Article

References (21)

1. Alloul, K and Sauriol, L and Kennedy, W and Laurier, C and Tessier, G and Novosel, S and Contandriopoulos, A. (1998) Alzheimer's disease: A review of the disease, its epidemiology and economic impact Gerontology and Geriatrics, 27, pp. 189 - 221.
2. Andreasen, N and Blennow, K. (2002) β-Amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease Peptides, 23, pp. 1205-1214.
3. Band, PR and Le, ND and Fang, R and Deschamps, M. (2002) Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer The Lancet, 360, pp. 1044-1049.
4. Blennow, K and Vanmechelen, E. (2003) CSF markers for pathogenic processes in Alzheimer's disease: Diagnostic implications and use in clinical neurochemistry Brain Research Bulletin, 61, pp. 235-242.
5. Box, GEP and Behnken, DW. (1960) Some new three level designs for the study of quantitative variables Technometrics, 2, pp. 455-475.
6. Bridge, MH and Williams, E and Lyons, MEG and Tipton, KF and Linert, W. (2004) Electrochemical investigation into the redox activity of Fe(II)/ Fe(III) in the presence of nicotine and possible relations to neurodegenerative diseases Biochimica et Biophysica Acta-Molecular Basis Diseases, 1690, pp. 77-84.
7. DeMarini, DM. (2004) Genotoxicity of tobacco smoke and tobacco smoke condensate: A review Mutation Research/Reviews in Mutation Research, 567, pp. 447-474.
8. Hernandez, CM and Terry Jr, AV. (2005) Repeated nicotine exposure in rats: Effects on memory function, cholinergic markers and nerve growth factor Neuroscience, 130, pp. 997-1012.
9. Lemay, S and Blanchet, P and Chouinard, S and Masson, H and Soland, V and Bedard, MA. (2003) Poor tolerability of a transdermal nicotine treatment in Parkinson's disease Clinical Neuropharmacology, 26, pp. 227-229.
10. Lemay, S and Chouinard, S and Blanchet, P and Masson, H and Soland, V and Beuter, A and Bedard, MA. (2004) Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease Progress in Neuropsychopharmacology, Biology & Psychology, 28, pp. 31-39.
11. Liu, P and Krishnan, TR. (1999) Alginaate-pectin-poly-L-lysine particulate as a potential controlled release formulation Journal of Pharmaceutical Pharmacology, 51, pp. 141-149.
12. Newhouse, PA and Kelton, M. (2000) Nicotinic systems in central nervous systems disease: Degenerative disorders and beyond Pharmaceutica Acta Helvetica, 74, pp. 91-101.
13. Newhouse, PA and Potter, A and Singh, A. (2004) Effects of nicotinic stimulation on cognitive performance Current Opinions in Pharmacology, 4, pp. 36-46.
14. Ono, K and Hasegawa, K and Yamada, M and Naiki, H. (2002) Nicotine breaks down preformed Alzheimer's β-amyloid fibrils in vitro Biological Psychology, 52, pp. 880-886.
15. Pillay, V and Danckwerts, MP and Fassihi, R. (2002) A crosslinked calcium-alginate-pectinate-cellulose acetophthalate gelisphere system for linear drug release Drug Delivery, 9, pp. 77-86.
16. Pillay, V and Fassihi, R. (1999a) In vitro release modulation from crosslinked pellets for site-specific drug delivery to the gastrointestinal tract. II. Physicochemical characterization of calcium-alginate, calcium-pectinate and calcium-alginate-pectinate pellets Journal of Controlled Release, 59, pp. 243-256.
17. Pillay, V and Fassihi, R. (1999b) In vitro release modulation from crosslinked pellets for site-specific drug delivery to the gastrointestinal tract. I. Comparison of pH-responsive drug release and associated kinetics Journal of Controlled Release, 59, pp. 229-242.
18. Rusted, JM and Newhouse, PA and Levin, ED. (2000) Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease Behavioural Brain Research, 113, pp. 121-129.
19. Tammenmaa, IA and Sailas, E and McGrath, JJ and Soares-Weiser, K and Wahlbeck, K. (2004) Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: A meta-analysis of randomized controlled trials Progress in Neuro-Psychpharmaceutical Biology & Psychology, 28, pp. 1099-1107.
20. Walkenström, P and Kidman, S and Hermansson, AM and Rasmussen, PB and Hoegh, L. (2003) Microstructure and rheological behaviour of alginate/pectin mixed gels Food Hydrocolloids, 17, pp. 593-603.
21. Williams, E and Linert, W. (2004) In vitro evidence supporting the therapeutic role of nicotine against neurodegeneration In Vivo, 1, pp. 391-399.